New study lays groundwork for potential new anti-cancer therapy

June 08, 2016

Philadelphia, PA, June 8, 2016 - Identifying the cell of origin is crucial to understanding how a tumor develops and metastasizes and for developing targeted therapies. Researchers have found evidence supporting a lymphatic endothelium origin for angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), two related tumors with previously unknown cellular origins. Furthermore, the newly identified lymphatic endothelial lineage shows translational potential for pharmaceutical treatment. Their findings are published in The American Journal of Pathology.

"As both AML and LAM are tightly linked processes, they are thought to be different manifestations of a common process," explained lead investigatorLucia Nieto Schuger, MD, of the Department of Pathology at The University of Chicago. "As a result of our investigation of the cell of origin for an AML cell line derived from a LAM patient, we were able to suggest a potential novel origin for LAM mechanistically dependent upon TSC [tuberous sclerosis complex] inactivation as well."

The researchers used an AML-derived cell line to determine whether restitution (re-expression) of the TSC2 protein would promote differentiation into the cell type from which AML arises. In this cell line and histological sections of AMLs, several embryonic lymphatic endothelial cell (LEC) markers consistent with LEC precursors were expressed. Upon TSC2 correction, AML cells matured immunophenotypically into adult LECs and showed functional attributes of this lineage. Such lymphatic mimicry observed in many cancers represents a curious enigma, but the molecular mechanisms for a 'failed' or 'dysregulated' lymphatic system are striking, opening the door for development of improved therapies.

Previous clinical trials with rapamycin, the only FDA-approved drug for treating LAM and AML, have been only partially successful. Combined therapies with rapamycin followed by surgery, in the case of AML, or addition of second drug, particularly in the case of LAM, are therefore the focus of much attention.

The investigators found that the lymphangiogenesis inhibitor norcantharidin halted the proliferation of both TSC2+ and TSC2? AML cells in vitro. Norcantharidin used in combination with rapamycin also produced promising preliminary results. "These studies showed an additive effect between rapamycin and norcantharidin, demonstrating preliminary effectiveness in repurposing an anti-lymphangiogenic drug as co-adjuvant therapy for rapamycin and thereby presenting as a potential new therapeutic approach for patients suffering from AML and most likely for patients suffering from LAM," stated Dr. Schuger.

AMLs, the most common benign heterogeneous kidney tumors, are composed of blood vessels, smooth muscle cells, and fat cells featuring mutations in genes of the TSC cell growth pathway. Although most AMLs are benign, some tumors spread to local lymph nodes and may impair kidney function or ultimately lead to life-threatening retroperitoneal hemorrhage. These tumors frequently occur in patients suffering from LAM, a rare lung disease of borderline malignancy. The LAM nodules, which are indistinguishable from AML cells, tend to enlarge, proliferate, and cause cystic destruction of the lung leading to respiratory insufficiency.
-end-


Elsevier Health Sciences

Related Rapamycin Articles from Brightsurf:

Aging-US: 'From Causes of Aging to Death from COVID-19' by Mikhail V. Blagosklonny
Aging-US recently published ''From Causes of Aging to Death from COVID-19'' by Blagosklonny et al. which reported that COVID-19 is not deadly early in life, but mortality increases exponentially with age - which is the strongest predictor of mortality.

Muscle aging: Stronger for longer
With life expectancy increasing, age-related diseases are also on the rise, including sarcopenia, the loss of muscle mass due to aging.

An ISGlobal team achieves massive sexual conversion of the malaria parasite in a dish
The technique will facilitate the design of new tools to block disease transmission.

An exploratory study of metformin and rapamycin as maintenance therapy
Volume 11, Number 21 of @Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX.

Immune-regulating drug improves gum disease in mice
A drug that has life-extending effects on mice also reverses age-related dental problems in the animals, according to a new study published today in eLife.

Scientist proposes clinical trials with low-dose rapamycin to protect elderly from COVID-19
The Biogerontology Research Foundation, a registered UK charity supporting and promoting aging and longevity research worldwide since 2008, today announced the publication of a paper titled 'Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections' in the leading journal Aging.

The CNIO discovers that rapamycin has harmful effects when telomeres are short
The CNIO shows that an anti-aging strategy that extends life in normal mice, the treatment with rapamycin, is harmful when mice have short telomeres.

Rapamycin may slow skin aging, Drexel study reports
The search for youthfulness typically turns to lotions, supplements, serums and diets, but there may soon be a new option joining the fray.

Study: Rapamycin prevents age-related brain vascular deterioration
A newly released study found that rats of advanced age, treated with the drug rapamycin, maintained superior blood flow to the brain compared to younger, untreated rats.

Rapamycin for longevity -- Opinion article
The scientist discusses several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today.

Read More: Rapamycin News and Rapamycin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.